An expert discusses how atopic dermatitis creates significant physical and quality-of-life burdens affecting up to 20% of pediatric and 10% of adult patients globally, with presentations varying across age groups and key unmet needs including improved access to care and disease recognition across different skin tones.
Sonia Batra, MD, shares effective summer acne solutions using lasers such as Aerolase Neo Elite and AviClear, ensuring tailored care for optimal skin health.
Explore insights on benzoyl peroxide and benzene risks in acne treatment from experts Renata Block, DMSc, MMS, PA-C, and John Barbieri, MD, MBA.
Sonia Batra, MD, dispels common myths and shares expert tips on summer skin care for acne, emphasizing sun protection and tailored regimens.
Renata Block, DMSc, MMS, PA-C, speaks with Adam Friedman, MD, FAAD, on innovative teledermatology initiatives in Washington, DC, addressing health care disparities and enhancing community access.
Iris Rubin, MD, highlights SEEN's science-backed hair care, designed for acne-prone skin, improving scalp health and reducing irritation.
UC Berkeley’s Broc Vargo shares how growing up in tanning salons inspired his passion for dermatology, sun safety, and public health advocacy.
Iris Rubin, MD, reveals how her brand SEEN transforms hair products to combat acne, promoting clearer skin through innovative, skin-friendly formulations.
Pediatric dermatologist Mercedes E. Gonzalez, MD, discusses roflumilast's promise as a safe, nonsteroidal treatment for atopic dermatitis in infants.
At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.
Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.
At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.
Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.
Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.
At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.
At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.
At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from severe AD flares, and the role of targeted non-steroidal and systemic therapies.
At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.
At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.
At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.
At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.
At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.
Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.
Tristan Hasbargen, PA-C, led a hands-on suturing workshop at the Fall Clinical NP/PA Conference, enhancing skills in surgical dermatology.
In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.
Jonathan Silverberg, MD, PhD, MPH, walks through what to look out for in AD management.
In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.
Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.
Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.
Heather Gates, PA-C, shares insights on the importance of continuous learning, mentorship, and legislative reform for PAs and NPs in dermatology.
